REAL-TIME GLOBAL RESEARCH
CSL Ltd | Asia Pacific FY26 Result: First Take
Research evidence excerpt
Not for redistribution without written consent of Morgan Stanley
M
Update
August 17, 2026 10:49 PM GMT
Morgan Stanley Australia Limited+
CSL Ltd | Asia Pacific
David L Bailey
Equity Analyst
FY26 Result: First Take
Peter Niu
Research Associate
AlphaSignals Earnings Reaction
Unchanged
Modest upside
Modest revision higher
Impact to our thesis
Financial results versus consensus
Direction of next 12-month
consensus EPS
Source: Company data, Morgan Stanley Research
CSL Ltd (CSL.AX, CSL AU)
Key Takeaways
Australia Healthcare | Australia
The beats: FY26 revenue and gross profit ahead of expectations for all segments;
Ig and albumin revenue +3% vs VA. Cost savings of US$176mn.
The misses: FY26 SG&A ahead of expectations; R&D slightly ahead.
FY27 outlook: Underlying NPAT growth of +5% on a base of US$2,837mn. When
including a lower IP amortisation charge, this implies NPATA growth of +2%.
For FY27, CSL expects mid single-digit growth for CSL Behring, low single-digit
growth for Seqirus and a ~25% revenue decline for Vifor.
Exhibit 1:
CSL FY26 result
FY25
Actual
FY26
YoY
VA
Revenue
Behring
Seqirus
Vifor
Group
11,158
2,166
2,234
15,558
11,387
2,031
2,379
15,797
2.1%
-6.2%
6.5%
1.5%
11,133
1,994
2,303
15,410
Gross profit
Behring
Seqirus
Vifor
Group
5,641
1,257
1,545
8,443
5,648
1,151
1,655
8,454
0.1%
-8.4%
7.1%
0.1%
Gross margin
Behring
Group
50.6%
54.3%
49.6%
53.5%
Group
SG&A
R&D
SG&A/revenue
R&D
EBIT
…EBIT margin
Net interest
PBT
Tax
…Tax rate
NPATA
Minorities
NPATA attributable
2,616
1,359
16.8%
8.7%
4,468
28.7%
410
4,058
645
15.9%
3,413
194
3,219
2,611
1,223
16.5%
7.7%
4,620
29.2%
405
4,215
879
20.9%
3,336
238
3,098
Variance
MS
VA
MS
10,980
2,004
2,279
15,263
2.3%
1.8%
3.3%
2.5%
3.7%
1.3%
4.4%
3.5%
5,530
1,105
1,556
8,205
5,443
1,156
1,548
8,146
2.1%
4.2%
6.4%
3.0%
3.8%
-0.4%
6.9%
3.8%
-1.0%
-1.4%
49.7%
53.2%
49.6%
53.4%
-0.1%
0.3%
0.0%
0.1%
-0.2%
-10.0%
-29bps
-99bps
3.4%
53bps
-1.2%
3.9%
36.3%
496bps
-2.3%
22.7%
-3.8%
2,493
1,217
16.2%
7.9%
4,475
29.0%
386
4,090
796
19.5%
3,281
216
3,078
2,470
1,179
16.2%
7.7%
4,497
29.5%
394
4,103
780
19.0%
3,324
219
3,105
4.7%
0.5%
35bps
-16bps
3.2%
21bps
5.0%
3.1%
10.4%
139bps
1.7%
10.4%
0.6%
5.7%
3.8%
35bps
2bps
2.7%
-22bps
2.8%
…
The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.
Open report viewer